XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 29.81

-4.3%

Dec 2 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (9494)	4/1/1999 10:11:00 PM
From: aknahow	Read Replies (1) of 17367

Bluegreen from the Fact Sheet. XMP300 anti-angiogenic compounds chronic inflammation metastatic tumors Pre-clinical Internal program XMP600 anti-endotoxin compounds endotoxin neutralization Preclinical Internal program They talk specifically about taking two products into clinic. Then table list only two as pre clinical. Can you say anti angiogenesis? Perhaps there are coat tails but much depends on timing. If it takes 6 months after the Sugen "blast" I see an independent impact. If going into clinic within 30 days from now then yes some impact. If P III Meningo is a success and provides T.V. story within 3 months, then XOMA may have opportunity to talk about other prospects. But really in spite of my time frames I have no idea. Just setting up Robert S to have to search for this post when none of it comes true. Perhaps he is smart and just bookmarks our dumb post. No, would not save much time searching.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next